- Home
- LGND vs KNSA Comparison
LGND vs KNSA Comparison
Compare LGND & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LGND | KNSA |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | United Kingdom |
| Employees | 68 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.4B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | LGND | KNSA |
|---|---|---|
| Price | $201.74 | $45.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $245.17 | $55.29 |
| AVG Volume (30 Days) | 155.0K | ★ 545.6K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | N/A | ★ 0.75 |
| Revenue | N/A | ★ $677,564,000.00 |
| Revenue This Year | $0.74 | $38.01 |
| Revenue Next Year | $19.04 | $17.42 |
| P/E Ratio | $76.27 | ★ $61.53 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $93.58 | $18.26 |
| 52 Week High | $212.49 | $49.12 |
Technical Indicators
Market Signals| Indicator | LGND | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 57.47 | 54.98 |
| Support Level | $198.52 | $40.47 |
| Resistance Level | $207.72 | $49.12 |
| Average True Range (ATR) | 8.10 | 2.18 |
| MACD | 2.09 | -0.01 |
| Stochastic Oscillator | 75.45 | 60.63 |
Price Performance
Historical ComparisonAbout LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.